Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis

BACKGROUND & AIMS: Research on vasopressin (AVP) in cirrhosis and its role in the assessment of prognosis has been hindered by the difficulty of measuring AVP levels accurately. Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together with AVP. Copeptin could have a r...

Descripción completa

Detalles Bibliográficos
Autores: Solà, Elsa, Kerbert, Annarein J. C., Verspaget, Hein W., Moreira, Rebeca, Pose Méndez, Elisa, Ruiz, Pablo, Cela, Raquel, Morales Ruiz, Manuel, López, Eva, Graupera, Isabel, Solé Padullés, Cristina, Huelin, Patricia, Amorós, Àlex, Ariza Piquer, Xavier, Jalan, Rajiv, Fabrellas i Padrès, Núria, Benten, Daniel, de la Prada, Gloria, Durand, François, Jiménez Povedano, Wladimiro, Reijden, Johan J. van der, Fernández, Javier, Hoek, Bart van, Coenraad, Minneke J., Ginès i Gibert, Pere
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2016
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/125224
Acceso en línea:https://hdl.handle.net/2445/125224
Access Level:acceso abierto
Palabra clave:Cirrosi hepàtica
Marcadors bioquímics
Pronòstic mèdic
Hepatic cirrhosis
Biochemical markers
Prognosis
id ES_cb107277bdfe0967ec0fc4c8c242e1a2
oai_identifier_str oai:diposit.ub.edu:2445/125224
network_acronym_str ES
network_name_str España
repository_id_str
spelling Plasma copeptin as biomarker of disease progression and prognosis in cirrhosisSolà, ElsaKerbert, Annarein J. C.Verspaget, Hein W.Moreira, RebecaPose Méndez, ElisaRuiz, PabloCela, RaquelMorales Ruiz, ManuelLópez, EvaGraupera, IsabelSolé Padullés, CristinaHuelin, PatriciaAmorós, ÀlexAriza Piquer, XavierJalan, RajivFabrellas i Padrès, NúriaBenten, Danielde la Prada, GloriaDurand, FrançoisJiménez Povedano, WladimiroReijden, Johan J. van derFernández, JavierHoek, Bart vanCoenraad, Minneke J.Ginès i Gibert, PereCirrosi hepàticaMarcadors bioquímicsPronòstic mèdicHepatic cirrhosisBiochemical markersPrognosisBACKGROUND & AIMS: Research on vasopressin (AVP) in cirrhosis and its role in the assessment of prognosis has been hindered by the difficulty of measuring AVP levels accurately. Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together with AVP. Copeptin could have a role as biomarker of prognosis in cirrhosis as it may reflect circulatory dysfunction. The aim of this study is to investigate the role of copeptin as biomarker of disease progression and prognosis in cirrhosis. METHODS: This prospective study is divided in 2 study protocols including 321 consecutive patients. Plasma copeptin levels were measured in all patients at study inclusion. Protocol 1: to investigate the relationship of copeptin with kidney and circulatory function (56 patients). Protocol 2: to investigate the relationship between copeptin and prognosis, as assessed by the development of complications of cirrhosis or mortality at 3months (265 patients admitted to hospital for complications of cirrhosis). RESULTS: Patients with decompensated cirrhosis showed significantly higher plasma copeptin levels compared to those of patients with compensated cirrhosis. Copeptin levels had a significant positive correlation with model for end-satge liver disease (MELD) score, AVP, endogenous vasoconstrictor systems, and kidney function parameters. Patients developing complications of cirrhosis or mortality had significantly higher plasma copeptin levels compared to those of the remaining patients. Plasma copeptin levels were an independent predictive factor of both the development of complications and mortality at 3months. This was confirmed in a validation series of 120 patients. CONCLUSIONS: Copeptin is a novel biomarker of disease progression and prognosis in cirrhosis. LAY SUMMARY: Copeptin is a fragment of the vasopressin precursor, a hormone that is known to be increased in patients with cirrhosis and that plays a role in the development of complications of the disease. Vasopressin is difficult to measure, but copeptin is a more stable molecule and is easier to measure in blood. Solà and Kerbert and colleagues have shown in a series of 361 patients that copeptin is markedly increased in patients with cirrhosis who develop complications during the following 3months, compared to those patients who do not develop complications. Moreover, copeptin correlates with prognosis.Elsevier2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/125224Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2016.07.003Journal of Hepatology, 2016, vol. 65, num. 5, p. 914-920https://doi.org/10.1016/j.jhep.2016.07.003cc-by-nc-nd (c) Elsevier, 2016http://creativecommons.org/licenses/by-nc-nd/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1252242026-05-27T06:46:51Z
dc.title.none.fl_str_mv Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
title Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
spellingShingle Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
Solà, Elsa
Cirrosi hepàtica
Marcadors bioquímics
Pronòstic mèdic
Hepatic cirrhosis
Biochemical markers
Prognosis
title_short Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
title_full Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
title_fullStr Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
title_full_unstemmed Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
title_sort Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
dc.creator.none.fl_str_mv Solà, Elsa
Kerbert, Annarein J. C.
Verspaget, Hein W.
Moreira, Rebeca
Pose Méndez, Elisa
Ruiz, Pablo
Cela, Raquel
Morales Ruiz, Manuel
López, Eva
Graupera, Isabel
Solé Padullés, Cristina
Huelin, Patricia
Amorós, Àlex
Ariza Piquer, Xavier
Jalan, Rajiv
Fabrellas i Padrès, Núria
Benten, Daniel
de la Prada, Gloria
Durand, François
Jiménez Povedano, Wladimiro
Reijden, Johan J. van der
Fernández, Javier
Hoek, Bart van
Coenraad, Minneke J.
Ginès i Gibert, Pere
author Solà, Elsa
author_facet Solà, Elsa
Kerbert, Annarein J. C.
Verspaget, Hein W.
Moreira, Rebeca
Pose Méndez, Elisa
Ruiz, Pablo
Cela, Raquel
Morales Ruiz, Manuel
López, Eva
Graupera, Isabel
Solé Padullés, Cristina
Huelin, Patricia
Amorós, Àlex
Ariza Piquer, Xavier
Jalan, Rajiv
Fabrellas i Padrès, Núria
Benten, Daniel
de la Prada, Gloria
Durand, François
Jiménez Povedano, Wladimiro
Reijden, Johan J. van der
Fernández, Javier
Hoek, Bart van
Coenraad, Minneke J.
Ginès i Gibert, Pere
author_role author
author2 Kerbert, Annarein J. C.
Verspaget, Hein W.
Moreira, Rebeca
Pose Méndez, Elisa
Ruiz, Pablo
Cela, Raquel
Morales Ruiz, Manuel
López, Eva
Graupera, Isabel
Solé Padullés, Cristina
Huelin, Patricia
Amorós, Àlex
Ariza Piquer, Xavier
Jalan, Rajiv
Fabrellas i Padrès, Núria
Benten, Daniel
de la Prada, Gloria
Durand, François
Jiménez Povedano, Wladimiro
Reijden, Johan J. van der
Fernández, Javier
Hoek, Bart van
Coenraad, Minneke J.
Ginès i Gibert, Pere
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cirrosi hepàtica
Marcadors bioquímics
Pronòstic mèdic
Hepatic cirrhosis
Biochemical markers
Prognosis
topic Cirrosi hepàtica
Marcadors bioquímics
Pronòstic mèdic
Hepatic cirrhosis
Biochemical markers
Prognosis
description BACKGROUND & AIMS: Research on vasopressin (AVP) in cirrhosis and its role in the assessment of prognosis has been hindered by the difficulty of measuring AVP levels accurately. Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together with AVP. Copeptin could have a role as biomarker of prognosis in cirrhosis as it may reflect circulatory dysfunction. The aim of this study is to investigate the role of copeptin as biomarker of disease progression and prognosis in cirrhosis. METHODS: This prospective study is divided in 2 study protocols including 321 consecutive patients. Plasma copeptin levels were measured in all patients at study inclusion. Protocol 1: to investigate the relationship of copeptin with kidney and circulatory function (56 patients). Protocol 2: to investigate the relationship between copeptin and prognosis, as assessed by the development of complications of cirrhosis or mortality at 3months (265 patients admitted to hospital for complications of cirrhosis). RESULTS: Patients with decompensated cirrhosis showed significantly higher plasma copeptin levels compared to those of patients with compensated cirrhosis. Copeptin levels had a significant positive correlation with model for end-satge liver disease (MELD) score, AVP, endogenous vasoconstrictor systems, and kidney function parameters. Patients developing complications of cirrhosis or mortality had significantly higher plasma copeptin levels compared to those of the remaining patients. Plasma copeptin levels were an independent predictive factor of both the development of complications and mortality at 3months. This was confirmed in a validation series of 120 patients. CONCLUSIONS: Copeptin is a novel biomarker of disease progression and prognosis in cirrhosis. LAY SUMMARY: Copeptin is a fragment of the vasopressin precursor, a hormone that is known to be increased in patients with cirrhosis and that plays a role in the development of complications of the disease. Vasopressin is difficult to measure, but copeptin is a more stable molecule and is easier to measure in blood. Solà and Kerbert and colleagues have shown in a series of 361 patients that copeptin is markedly increased in patients with cirrhosis who develop complications during the following 3months, compared to those patients who do not develop complications. Moreover, copeptin correlates with prognosis.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/125224
url https://hdl.handle.net/2445/125224
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2016.07.003
Journal of Hepatology, 2016, vol. 65, num. 5, p. 914-920
https://doi.org/10.1016/j.jhep.2016.07.003
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier, 2016
http://creativecommons.org/licenses/by-nc-nd/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier, 2016
http://creativecommons.org/licenses/by-nc-nd/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419533778812928
score 15,300724

Similares en LA Referencia